ファーマナビゲーター　ビスフォスフォネート編

出版社： メディカルレビュー社
著者：
発行日： 2005-05-20
分野： 臨床医学：外科  >  整形外科学
ISBN： 4896008251
シリーズ： ファーマナビゲーター
電子書籍版： 2005-05-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,650 円(税込)

購入する

商品紹介

本書は、現在の骨粗鬆症治療の中心となっているビスフォスフォネート製剤に関する最新の情報を満載するとともに、Q＆Ａ形式によりビスフォスフォネート治療の実際についてもわかりやすく解説している。

目次

  • ファーマナビゲーター　ビスフォスフォネート編

    ―目次―

    Chapter 1　ビスフォスフォネート製剤とは
    Chapter 2　骨粗鬆症の分類と病態
    Chapter 3　骨粗鬆症と骨折
    Chapter 4　骨粗鬆症の治療とビスフォスフォネート
    Chapter 5　EBM
    Chapter 6　骨質とビスフォスフォネート
    Chapter 7　ビスフォスフォネート治療の実際Q&A
    Chapter 8　使用上の注意と対応
    Chapter 9　治療効果の判定
    Chapter 10　癌に伴う骨病変とビスフォスフォネート

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter 1 ビスフォスフォネート製剤とは

P.31 掲載の参考文献
1) 篠田壽 : ビスフォスフォネートの構造と薬理作用. THE BONE 13 : 31-40, 1999
Medical*Online
2) 小澤英浩, 川島博行, 高橋俊二 : World of Bisphosphonate (尾形悦郎監) , メディカルレビュー社, 東京, 2001, p.1-39
 
3) Murakami H, Takahashi N, Sasaki T et al : A possible mechanism of the specific action of bisphosphonates on osteoclasts : tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 : 137-144, 1995
 
4) Endo Y, Nakamura M, Kikuchi T et al : Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 52 : 248-254, 1993
PubMed
5) Thompson DD, Seedor JG, Weinreb M et al : Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res 5 : 279-286, 1990
PubMed
6) Kodama H, Yamasaki A, Abe M et al : Transient recruitment of osteoclasts and expression of their function in osteopetrotic (op/op) mice by a single injection of macrophage colony-stimulating factor. J Bone Miner Res 8 : 45-50, 1993
PubMed
7) Takami M, Suda K, Sahara T et al : Involvement of vacuoIar H＋ -ATPase in incorporation of risedronate into osteoclasts. Bone 32 : 341-349, 2003
PubMed
8) Rogers MJ, Frith JC, Luckman SP et al : Molecular mechanisms of action of bisphosphonates. Bone 5 (Suppl) : 73S-79S, 1999
 
9) Fisher JE, Rogers MJ, Halasy JM et al : Alendronate mechanism of action : geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96 : 133-138, 1999
PubMed
10) Reszka AA, Halasy-Nagy JM, Masarachia PJ et al : Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst 1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of anapoptosis-promoting kinase. J Biol Chem 274 : 34967-34973, 1999
 
11) Coxon FP, Helfrich MH, Larijani B et al : Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276 : 48213-48222, 2001
PubMed
12) Thompson K, Dunford JE, Ebetino FH et al : Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 290 : 869-873, 2002
PubMed
13) Benford HL, Frith JC, Auriola S et al : Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates : biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56 : 131-140, 1999
PubMed

Chapter 2 骨粗鬆症の分類と病態

P.41 掲載の参考文献
1) Consensus Development Conference : Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 : 646-650, 1993
PubMed
2) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy : Osteoporosis prevention, diagnosis, and therapy. JAMA 285 : 785-795, 2001
PubMed
3) 折茂肇, 杉岡洋一, 福永仁夫ほか : 原発性骨粗鬆症の診断基準 (1996年度改訂版). 日骨代謝誌 14 : 219-233, 1997
 
4) 折茂肇, 林泰史, 福永仁夫ほか : 原発性骨粗鬆症の診断基準 (2000年度改訂版). 日骨代謝誌 18 : 76-82, 2001
 
5) Eastell R : Pathogenesis of postmenopausalo steoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed., The American Society for Bone and Mineral Research, 2003, p.314-316
 
6) Khovidhunkit W, Epstein S : Osteoporosis in pregnancy. Osteoporos Int 6 : 345-354, 1996
PubMed
7) Norman ME : Juvenile osteoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed., The American Society for Bone and Mineral Research, 2003, p.382-386
 
8) Lakatos P : Thyroid hormones : beneficial or deleterious for bone?Calcif Tissue Int 73 : 205-209, 2003
 
9) Stein E, Shane E : Secondary osteoporosis. Endocrinol Metab Clin North Am 32 : 115-134, 2003
PubMed
10) Kaltsas G, Manetti L, Grossman AB : Osteoporosis in Cushing's syndrome. Front Horm Res 30 : 60-72, 2002
PubMed
11) Sambrook PN : Glucocorticoid osteoporosis. Curr Pharm Des 8 : 1877-1883, 2002
PubMed
12) Tannirandorn P, Epstein S : Drug-induced bone loss. Osteoporos Int 11 : 637-659, 2000
PubMed
13) Pfeilschifter J, Diel IJ : Osteoporosis due to cancer treatment : pathogenesis and management. J Clin Oncol 18 : 1570-1593, 2000
PubMed
14) Watanabe Y, Ohshima H, Mizuno K et al : Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 19 : 1771-1778, 2004
 
15) Carmeliet G, Vico L, Bouillon R : Space flight : a challenge for normal bone homeostasis. Crit Rev Eukaryot Gene Expr 11 : 131-144, 2001
PubMed
16) Takata S, Yasui N : Disuse osteoporosis. J Med Invest 48 : 147-156, 2001
 
17) Westhovens R, Dequeker J : Rheumatoid arthritis and osteoporosis. Z Rheumatol 59 (Suppl 1) : 33-38, 2000
 
18) Hay JE : Osteoporosis in liver diseases and after liver transplantation. J Hepatol 38 : 856-865, 2003
PubMed

Chapter 3 骨粗鬆症と骨折

P.48 掲載の参考文献
1) 山本逸雄 : 骨粗鬆症人口の推定. Osteoporos Jpn 7 : 10-11, 1999
 
2) Fujiwara S, Kasagi F, Masunari N et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18 : 1547-1553, 2003
PubMed
3) The European Prospective Osteoporosis Study (EPOS) Group : Incidence of vertebral fracture in europe : results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner, Res 17 : 716-724, 2002
PubMed
4) Van der Klift M, De Laet CE, McCloskey EV et al : The incidence of vertebral fracture in men and women : The Rotterdam Study. J Bone Miner Res 17 : 1051-1056, 2002
PubMed
5) Hagino H, Yamamoto K, Ohshiro H et al : Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 24 : 265-270, 1999
PubMed
6) Kanis JA, Johnell O, De Laet C et al : International variations in hip fracture probabilities : implication for risk assessment. J Bone Miner Res 17 : 1237-1244, 2002
PubMed
7) Marshall D, Johnell O, Wedel H : Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 : 1254-1259, 1996
PubMed
8) Kanis JA, Johnell O, De Laet C et al : Ameta-analysis of previous fracture and subsequent fracture risk. Bone 35 : 375-382, 2004
 
9) Klotzbuecher CM, Ross PD, Landsman PB et al : Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis. J Bone Miner Res 15 : 721-739, 2000
PubMed
10) Vestergaard P, Mosekilde L : Fracture risk associated with smoking : a meta-analysis. J Intern Med 254 : 572-583, 2003
PubMed
11) Kanis JA, Johnell O, Oden A et al : Smoking and fracture risk : a meta-analysis. Osteoporos Int (in press)
 
12) Kanis JA, Johansson H, Oden A et al : A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 : 893-899, 2004
 
13) van Staa TP, Leufkens HG, Cooper C : The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int 13 : 777-787, 2002
PubMed
14) Kanis JA, Johansson H, Oden A et al : A family history of fracture and fracture risk : ameta-analysis. Bone 35 : 1029-1037, 2004
 

Chapter 4 骨粗鬆症の治療とビスフォスフォネート

P.61 掲載の参考文献
1) Albright F, Smith PH, Richardson AM : Postmenopausal osteoporosis. JAMA 116 : 2465-2474, 1941
 
2) Riggs BL, Melton JL 3rd : Involutional osteoporosis. N Engl J Med 314 : 1676-1686, 1986
 
3) Meunier PJ, Delmas PD, Eastell R et al : Diagnosis and management of osteoporosis in postmenopausal women : clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 21 : 1025-1044, 1999
PubMed
4) Fujiwara S, Fukunaga M, Nakamura T et al : Rates of change in spinal bone density among Japanese women. Calcif Tissue Int 63 : 202-207, 1998
PubMed
5) Ito M, Nakamura T, Tsurusaki K et al : Effects of menopause on age-dependent bone loss in axial and appendicular skeletons in healthy Japanese women. Osteoporos Int 10 : 377-383, 1999
PubMed
6) Garnero P, Sornay-Rendu E, Chapuy MC et al : Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11 : 337-349, 1996
 
7) Khosla S, Atkinson EJ, Melton JL 3rd et al : Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women : a population-based study. J Clin Endocrinol Metab 82 : 1522-1527, 1997
 
8) Gallagher JC, Riggs BL, Eisman J et al : Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients : effect of age and dietary calcium. J Clin Invest 64 : 729-736, 1979
PubMed
9) Prince RL, Dick I, Devine A et al : The effects of menopause and age on calcitropic hormones : a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res 10 : 835-842, 1995
PubMed
10) Eriksen EF, Colvard DS, Berg NJ et al : Evidence of estrogen receptors in normalhuman osteoblast-like cells. Science 241 : 84-86, 1988
 
11) Oursler MJ, Osdoby P, Pyfferoen J et al : Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88 : 6613-6617, 1991
PubMed
12) Lindsay R, Hart DM, Aitken JM et al : Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1 : 1038-1041, 1976
PubMed
13) McKane WR, Khosla S, Burritt MF et al : Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause-a clinical research center study. J Clin Endocrinol Metab 80 : 3458-3464, 1995
PubMed
14) Ledger GA, Burritt MF, Kao PC et al : Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 80 : 3304-3310, 1995
PubMed
15) Prestwood KM, Pilbeam CC, Burleson JA et al : The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79 : 366-371, 1994
 
16) McKane WR, Khosla S, Risteli J et al : Role of estrogen deficiency in pathogenesis of secondary hyperparathyroidism and increased bone resorption in elderly women. Proc Assoc Am Physicians 109 : 174-180, 1997
PubMed
17) Epstein S, Bryce G, Hinman JW et al : The influence of age on bone mineral regulating hormones. Bone 7 : 421-425, 1986
 
18) Greendale GA, Edelstein S, Barrett-Connor E : Endogenous sex steroids and bone mineral density in older women and men : the Rancho Bernardo Study. J Bone Miner Res 12 : 1833-1843, 1997
 
19) Riggs BL, Khosla S, Melton LJ 3rd : A unitary model for involutional osteoporosis : estrogen deficiency causes both type I and II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13 : 763-773, 1998
 
20) Bilezikian JP : Estrogens and postmenopausal osteoporosis : was Albright right after all? J Bone Miner Res 13 : 774-776, 1998
 
21) Braga de Castro Machado A, Hannon R, Eastell R : Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14 : 602-608, 1999
 
22) Shiraki M, Kushida K, Fukunaga M et al : A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10 : 183-192, 1999
PubMed
23) Bone HG, Hosking D, Devogelaer JP et al : Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004
PubMed
24) Rodan G, Reszka A, Golub E et al : Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20 : 1291-1300, 2004
PubMed
25) Masarachia P, Weinreb M, Balena R et al : Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 : 281-290, 1996
 
P.76 掲載の参考文献
1) Nawata H, Soen S, Takayanagi R et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of The Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23 : 105-109, 2005
PubMed
2) Weinstein RS, Chen JR, Powers CC et al : Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109 : 1041-1048, 2002
PubMed
3) Weinstein RS, Jilka RL, Parfitt AM et al : Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of theirdeleterious effects on bone. J Clin Invest 102 : 274-282, 1998
 
4) Hermus AR, Smals AG, Swinkels LM et al : Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80 : 2859-2865, 1995
 
5) Gong Y, Slee RB, Fukai N et al : . LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 : 513-523, 2001
PubMed
6) Kato M, Patel MS, Levasseur R et al : Cbfal-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157 : 303-314, 2002
 
7) Boyden LM, Mao J, Belsky J et al : High bone density due to a mutation in LDL-receptor-relatedprotein 5. N Engl J Med 346 : 1513-1521, 2002
 
8) Ohnaka K, Taniguchi H, Kawate H et al : Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts : novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys, Res Commun 318 : 259-264, 2004
PubMed
9) Ohnaka K, Tanabe M, Kawate H et al : Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329 : 177-181, 2005
PubMed
10) Smith E, Frenkel B : Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in aglycogen synthase kinase-3β-dependent and -independent manner. J Biol Chem 280 : 2388-2394, 2005
 
11) 田中郁子, 大島久二 : ステロイド性骨粗鬆症の診断と治療に関する縦断研究 : 診断・治療指針への予備的検討. Osteoporos Jpn 11 : 11-14, 2003
 
12) van Staa TP, Leufkens HG, Cooper C : The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int 13 : 777-787, 2002
PubMed
13) 折茂肇, 林泰史, 福永仁夫ほか : 原発性骨粗鬆症の診断基準 (2000年度改訂版). 日骨代謝誌 18 : 76-82, 2001
 
14) 高柳涼一, 大中佳三, 河手久弥 : ステロイド骨粗鬆症の病態と治療指針. CLINICAL CALCIUM 13 : 134-140, 2003
 
15) de Nijs RN, Jacobs JW, Algra A et al : Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues : a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15 : 589-602, 2004
PubMed
16) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285 : 785-795, 2001
PubMed
17) Kanis JA, Johansson H, Oden A et al : A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 : 893-899, 2004
 
18) Ton FN, Gunawardene SC, Lee H et al : Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20 : 464-470, 2005
 
19) Plotkin LI, Aguirre JI, Kousteni S et al : Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280 : 7317-7325, 2005
PubMed
P.88 掲載の参考文献
1) Orstavik RE, Haugeberg G, Mowinckel P et al : Vertebral deformities in rheumatoid arthritis : a comparison with population-based controls. Arch Intern Med 164 : 420-425, 2004
PubMed
2) Hooyman JR, Melton LJ 3rd, Nelson AM et al : Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 27 : 1353-1361, 1984
PubMed
3) Kaz Kaz H, Johnson D, Kerry S et al : Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. Rheumatology (Oxford) 43 : 1267-1271, 2004
PubMed
4) Shibuya K, Hagino H, Morio Y et al : Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 21 : 150-158, 2002
PubMed
5) Teshima R, Hagino H, Kishimoto H et al : Radial and lumbar bone mineral density after wrist synovectomy in rheumatoid arthritis. A minimum 2-year follow-up in 10 unilaterally operated patients. Arch Orthop Trauma Surg 118 : 78-80, 1998
PubMed
6) Wetzel R, Puhl W, Brecht-Kraus D : The development of juxta-articular osteoporosis after synovectomy of the knee. A prospective study by double photon absorptiometry. Int Orthop 17 : 188-192, 1993
PubMed
7) 津田公子 : Dual X-rayabsorptiometryを用いた中手骨, 指節骨の骨量動態に関する研究. 日整会誌 67 : 1033-1044, 1993
 
8) Haugeberg G, Uhlig T, Falch JA et al : Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis : results from 394 patients in the Oslo Country rheumatoid arthritis register. Arthritis Rhuem 43 : 522-530, 2000
 
9) Gough AK, Lilley J, Eyre S et al : Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344 : 23-27, 1994
PubMed
10) Shimizu S, Shiozawa S, Shiozawa K et al : Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28 : 25-31, 1985
PubMed
11) Kroger H, Arnala I, Rehnberg V et al : Histomorphometry of periarticular bone in rheumatoid arthritis. Ann Chir Gynaecol 83 : 56-62, 1994
PubMed
12) Akesson K, Onsten I, Obrant KJ : Periarticular bone in rheumatoid arthritis versus arthrosis. Histomorphometry in 103 hip biopsies. Acta Orthop Scand 65 : 135-138, 1994
PubMed
13) 辻寿, 立石博臣, 楊鴻生ほか : RAの罹患膝関節周辺の骨の粗鬆化についての硬組織学的検討. 日関外誌 9 : 179-184, 1990
 
14) 横田徹 : 慢性関節リウマチの膝関節病変に関するX線学的および硬組織学的研究. リウマチ 36 : 503-513, 1996
 
15) 中野啓三 : 慢性関節リウマチ患者の骨の粗鬆化の関する腸骨を用いた硬組織学的検討. 臨床リウマチ 8 : 91-104, 1996
 
16) Perez-Edo L, Diez-Perez A, Marinoso L et al : Bone metabolism and histomorphometric changes in rheumatoid arthritis. Scand J Rheumatol 31 : 285-290, 2002
PubMed
17) Compston JE, Vedi S, Croucher PI et al : Bone turnover in nonsteroid treated rheumatoid arthritis. Ann Rheum Dis 53 : 163-166, 1994
PubMed
18) Cortet B, Flipo R, Pigny P et al : Is bone turnover a determinant of bone mass in rheumatoid arthritis?J Rheumatol 25 : 2339-2344, 1998
PubMed
19) Gough A, Sambrook P, Devlin J et al : Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25 : 1282-1289, 1998
PubMed
20) Al-Awadhi A, Olusi S, Al-Zaid N et al : Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 26 : 1250-1256, 1999
PubMed
21) Seriolo B, Ferretti V, Sulli A et al : Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci 966 : 502-507, 2002
PubMed
22) Iwamoto J, Takeda T, Ichimura S. Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis. Calcif Tissue Int 72 : 491-497, 2003
PubMed
23) Buckley LM, Leib ES, Cartularo KS et al : Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 24 : 1489-1494, 1997
PubMed
24) Cranney AB, McKendry RJ, Wells GA et al : The effect of low dose methotrexate on bone density. J Rheumatol 28 : 2395-2399, 2001
 
25) Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford). 41 : 741-749, 2002
 
26) Verstraeten A, Dequeker J : Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis : effect of low dose corticosteroids. Ann Rheum Dis 45 : 852-857, 1986
PubMed
27) Laan R, van Riel PL, van Erning LJ et al : Vertebral osteoporosis in rheumatoid arthritis patients : effect of low doseprednisone therapy. Br J Rheumatol 31 : 91-96, 1992
PubMed
28) Kalla AA, Bewerunge L, Langley A et al : Trabecular bone density in premenopausal rheumatoid arthritis patients. S Afr Med J 92 : 62-68, 2002
PubMed
29) van Staa TP, Leufkens HG, Cooper C : The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int. 13 : 777-787, 2002
PubMed
30) Lange U, Illgner U, Teichmann J et al : Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis : a prospective study. Int J Clin Pharmacol Res 24 : 33-38, 2004
PubMed
31) Yilmaz L, Ozoran K, Gunduz OH et al : Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 20 : 65-69, 2001
PubMed
32) Yamane I, Hagino H, Okano T et al : Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. Arthritis Rheum 48 : 1732-1741, 2003
 
33) Maccagno A, Di Giorgio E, Roldan EJ et al : Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 23 : 211-214, 1994
PubMed
34) Cantatore FP, Introsso AM, Carrozzo M : Effects of bisphosphonates on interleukin 1, tumor necrosis factorα, and β2 microglobulin in rheumatoid arthiritis. J Rheumatol 23 : 1117-1118, 1996
 
35) Valleala H, Laitinen K, Pylkkanen L et al : Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis--a double blind placebo controlled study. Inflamm Res 50 : 598-601, 2001
PubMed
36) Cantatore FP, Acquista CA, Pipitone V : Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26 : 2318-2323, 1999
PubMed
37) Ostanek L, Pawlik A, Brzosko I et al : The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infhximab. Clin Rheumatol 23 : 214-217, 2004
PubMed
38) Hermann J, Mueller T, Fahrleitner A et al : Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factorα antibody infliximab. Clin Exp Rheumatol 21 : 473-476, 2003
 
39) Allali F, Breban M, Porcher R et al : Increase in bone mineral density of patients with spondyloarthropathy treated with antitumour necrosis factorα. Ann Rheum Dis 62 : 347-349, 2003
 
40) Hall GM, Daniels M, Doyle DV et al : Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37 : 1499-1505, 1994
 
P.100 掲載の参考文献
1) Bikle DD, Halloran BP : The response of bone tou nloading. J Bone Miner Metab 17 : 233-244, 1999
 
2) Morey ER, Baylink DJ : Inhibition of bone formation during space flight. Science 201 : 1138-1141, 1978
PubMed
3) Smith SM, Nillen JL, Leblanc A et al : Collagen cross-link excretion during space flight and bed rest. J Clin Endocrinol Metab 83 : 3584-3591, 1998
PubMed
4) Leblanc AD, Schneider VS, Evans HJ et al : Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 5 : 843-850, 1990
PubMed
5) Inoue M, Tanaka H, Moriwake T et al : Altered biochemical markers of bone turnover in humans during 120 days of bed rest. Bone 26 : 281-286, 2000
PubMed
6) Inoue D, Kido S, Matsumoto T : Transcriptional indution of fos B/δfosB gene by mechanical stress in osteoporosis. J Biol Chem 279 : 49795-49803, 2004
 
7) Nance PW, Schryvers O, Leslie W et al : Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil 80 : 243-251, 1999
PubMed
8) Chappard D, Minaire P, Privat C et al : Effects of tiludronate on bone loss inparaplegic patients. J Bone Miner Res 10 : 112-118, 1995
 
9) Kodama Y, Nakayama K, Fuse H et al : Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 12 : 1058-1067, 1997
PubMed
10) Watanabe Y, Ohshima H, Mizuno K et al : Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 19 : 1771-1778, 2004
 
11) Yuan ZZ, Jee WS, Ma YF et al : Parathyroid hormone therapy accelerates recovery from immobilization-induced osteopenia. Bone 17 : 219S-223S, 1995
PubMed
12) Moriyama I, Iwamoto J, Takeda T : Comparative effects of intermittent administration of human parathyroid hormone (1-34) on cancellous and cortical bone loss in tail-suspended and sciatic neurectomized young rats. J Orthop Sci 7 : 379-385, 2002
PubMed

Chapter 5 EBM

P.112 掲載の参考文献
1) Miller PD, Watts NB, Licata AA et al : Cyclical etidronate in the treatment of postmenopausal osteoporosis : efficacy and safety after seven years of treatment Am J Med 103 : 468-476, 1997
PubMed
2) Cranney A, Guyatt G, Griffith L et al : Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr, Rev 23 : 570-578, 2002
PubMed
3) 藤田拓男, 折茂肇, 井上哲郎ほか : 退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸二ナトリウム (EHDP) の二重盲検比較試験. Clin Eval 21 : 261-302, 1993
 
4) 藤田拓男, 折茂肇, 井上哲郎 : 骨粗鬆症に対するEHDPの用量設定試験. 基礎と臨床 28 : 447-486, 1994
Medical*Online
5) 折茂肇, 藤田拓男, 井上哲郎 : 骨粗鬆症に対するEHDPの用法設定試験 (第1報, 第2報). 基礎と臨床 28 : 487-540, 1994
 
6) Black DM, Cummings SR, Karpf DB et al : Randomised trial of effect of alendronateon risk of fracture in women with existing vertebral fractures. Lancet 348 : 1535-1541, 1996
PubMed
7) Cummings SR, Black DM, Thompson DE et al : Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Tria1. JAMA 280 : 2077-2082, 1998
 
8) Bone HG, Hosking D, Devogelaer JP et al : Ten years’experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004
 
9) Tonino RP, Meunier PJ, Emkey R et al : Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85 : 3109-3115, 2000
PubMed
10) 岸本英彰, 白木正孝, 福永仁夫ほか : 退行期骨粗鬆症に対するAlendronate錠の長期投与試験. 診療と新薬 35 : 19-41, 1998
 
11) Shiraki M, Kushida K, Fukunaga M et al : A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10 : 183-192, 1999
PubMed
12) Kushida K, Shiraki M, Nakamura T et al : The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis : a randomized, double-blind, activecontrolled, double-dummy trial. Curr Ther Res 63 : 606-620, 2002
 
13) Kushida K, Shiraki M, Nakamura T et al : Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis : a 3-year follow-up study. J Bone Miner Metab 22 : 462-468, 2004
PubMed
14) Harris ST, Watts NB, Genant HK et al : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 : 1344-1352, 1999
 
15) Reginster JY, Minne HW, Sorensen OH et al : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 : 83-91, 2000
 
16) McClung MR, Geusens P, Miller PD et al : Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 : 333-340, 2001
PubMed
17) Sorensen OH, Crawford GM, Mulder H et al : Long-term efficacy of risedronate : a 5-year placebo-controlled clinical experience. Bone 32 : 120-126, 2003
PubMed
18) Watts NB, Josse RG, Hamdy RC et al : Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88 : 542-549, 2003
 
19) Lanza FL, Hunt RH, Thomson AB et al : Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausalwomen. Gastroenterology 119 : 631-638, 2000
 
20) 岸本英彰, 串田一博, 白木正孝ほか : 退行期骨粗鬆症ならびに卵巣機能欠落に伴う骨量減少例に対するリセドロネート (NE-58095) の有効性および安全性の検討. Osteoporos Jpn 10 : 61-83, 2002
 
21) Fukunaga M, Kushida K, Kishimoto H et al : Acomparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis : a randomized controlled trial. Osteoporos Int 13 : 971-979, 2002
 
22) 串田一博, 岸本英彰, 白木正孝ほか : 骨粗鬆症患者に対するリセドロネート長期投与時の有効性と安全性の検討. Osteoporos Jpn 10 : 85-97, 2002
 
23) Kushida K, Fukunaga M, Kishimoto H et al : A comparison of incidences of veretebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate : a randomized, double-masked trial. J Bone Miner Metab 22 : 469-478, 2004
 
24) Heckman GA, Papaioannou A, Sebaldt RJ et al : Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3 : 6-11, 2002
 
25) Heaney RP : The bone remodeling transient : implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9 : 1515-1523, 1994
 
26) Boivin GY, Chavassieux PM, Santora AC et al : Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 : 687-694, 2000
PubMed
27) 森諭史 : 骨病態生理における骨吸収抑制に関する研究. 日骨代謝誌 19 : 17-20, 2001
 
P.122 掲載の参考文献
1) 萩野浩 : 大腿骨頸部骨折の発生率. 骨粗鬆症学-基礎と臨床の新しいパラダイム- 日本臨床 62 (Suppl 2) : 205-209, 2004
 
2) Orimo H, Hashimoto T, Sakata K et al : Trends in the incidence of hip fracture in Japan, 1987-1997 : the third nationwide survey. J Bone Miner Metab 18 : 126-131, 2000
PubMed
3) Hagino H, Yamamoto K, Ohshiro H et al : Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 24 : 265-270, 1999
PubMed
4) Morita Y, Endo N, Iga T et al : The incidence of cervical and trochanteric fractures of the proximal femur in 1999 in Niigata Prefecture, Japan. J Bone Miner Metab 20 : 311-318, 2002
PubMed
5) Chapurlat RD, Bauer DC, Nevitt M et al : Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures. Osteoporos Int 14 : 130-136, 2003
 
6) Klotzbuecher CM, Ross PD, Landsman PB et al : Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis. J Bone Miner Res 15 : 721-739, 2000
PubMed
7) 萩野浩 : 骨折とEBM. IIIその他の骨折. 骨粗鬆症治療 3 : 61-64, 2004
 
8) McClung MR, Geusens P, Miller PD et al : Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 : 333-340, 2001
PubMed
9) Black DM, Thompson DE, Bauer DC et al : Fracture risk reduction with alendronate in women with osteoporosis : the fracture intervention trial. J Clin Endocrinol Metab 85 : 4118-4124, 2000
 
10) 日本整形外科学会骨粗鬆症委員会 : 平成11年大腿骨頸部骨折発生頻度調査結果報告. 日整会誌 75 : 386-402, 2001
 
11) Aoyagi K, Ross PD, Davis JW et al : Falls among community-dwelling elderly in Japan. J Bone Miner Res 13 : 1468-1474, 1998
PubMed
12) 安村誠司 : 高齢者の転倒・骨折の頻度. 日医雑誌 122 : 1945-1949, 1999
 
13) 黒柳律雄, 松田達男, 伊藤晴夫ほか : 高齢者の転倒と骨粗鬆症との関連, および転倒予防のための運動・生活指導に関する研究. Osteoporos Jpn 7 : 571-576, 1999
 
14) 吉村典子 : 運動, 身体活動改善による骨折・骨粗鬆症予防のエビデンス. 日衛誌 58 : 328-337, 2003
 
15) Province MA, Hadley EC, Hornbrook MC et al : The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries : Cooperative Studies of Intervention Techniques. JAMA 273 : 1341-1347, 1995
PubMed
16) Campbell AJ, Robertson MC, Gardner MM et al : Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women. BMJ 315 : 1065-1069, 1997
PubMed
17) Okuizumi H, Harada A, Iwata H et al : Effect on the femur of a new hip fracture preventive system using dropped-weight impact testing. J Bone Miner Res 13 : 1940-1945, 1998
PubMed
18) Lauritzen JB, Petersen MM, Lund B : Effect of external hip protectors on hip fractures. Lancet 341 : 11-13, 1993
PubMed
19) Ekman A, Mallmin H, Michaelsson K et al : External hip protectors to prevent osteoporotic hip fractures. Lancet 350 : 563-564, 1997
PubMed
20) Kannus P, Parkkari J, Niemi S et al : Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343 : 1506-1513, 2000
PubMed
21) Harada A, Mizuno M, Takemura M et al : Hip fracture prevention trial using hip protectors in Japanese nursing homes. Osteoporos Int 12 : 215-221, 2001
PubMed
22) Cameron ID, Venman J, Kurrle SE et al : Hip protectors in agedcare facilities : a randomized trial of use by individual higher-risk residents. Age Ageing 30 : 477-481, 2001
PubMed
23) 原田敦 : ヒッププロテクターによる大腿骨頸部骨折の予防. 転倒とヒッププロテクター. THE BONE 17 : 49-52, 2003
 
24) Simpson RU, Thomas GA, Arnold AJ : Identification of 1,25 dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 260 : 8882-8884, 1985
PubMed
25) Bischoff HA, Stahelin HB, Dick W et al : Effects of vitamin D and calcium supplementation on falls : a randomized controlled trial. J Bone Miner Res 18 : 343-351, 2003
 
26) Verhaar HJ, Samson MM, Jansen PA et al : Muscle strength, functional mobility and vitamin D in older women. Aging (Milano) 12 : 455-460, 2000
PubMed
P.131 掲載の参考文献
1) Cranney A, Guyatt G, Griffith L et al : Meta-analyses of therapies for postmenopausal osteoporosis. IX : Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23 : 570-578, 2002
PubMed
2) 藤田拓男, 折茂肇, 井上哲郎ほか : 退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸二ナトリウム (EHDP) の二重盲検比較試験. Clin Eval 21 : 261-302, 1993
 
3) Ishida Y, Kawai S : Comparative efficacy of hormone replacement therapy, etidronate, calcitionin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis : The Yamaguchi Osteoporosis Prevention Study. Am J Med 117 : 549-555, 2004
 
4) Black DM, Cummings SR, Karpf DB et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 : 1535-1541, 1996
 
5) Cummings SR, Black DM, Thompson DE et al : Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Trial. JAMA 280 : 2077-2082, 1998
PubMed
6) Kushida K, Shiraki M, Nakamura T et al : The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis ; a randomized, double-blind, active-controlled, double-dummy trial. Curr Therap Res 63 : 606-620, 2002
 
7) Kushida K, Shiraki M, Nakamura T et al : Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis : a 3-year follow-up study. J Bone Miner Metab 22 : 462-468, 2004
PubMed
8) Harris ST, Watts NB, Genant HK et al : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 : 1344-1352, 1999
 
9) Reginster J, Minne HW, Sorensen OH et al : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 : 83-91, 2000
 
10) McClung MR, Geusens P, Miller PD et al : Effect of risedronate on therisk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 : 333-340, 2001
 
11) Kushida K, Fukunaga M, Kishimoto H et al : A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate : a randomized, double-masked trial. J Bone Miner Metab 22 : 469-478, 2004
 

Chapter 6 骨質とビスフォスフォネート

P.137 掲載の参考文献
1) Wasnich RD, Miller PD : Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 : 231-236, 2000
PubMed
2) Weinstein RS : True strength. J Bone Miner Res 15 : 621-625, 2000
PubMed
3) Burr DB, Turner CH, Naick P et al : Does microdamage accumulation affect the mechanical properties of bone? J Biomech 31 : 337-345, 1998
 
4) Mashiba T, Hirano T, Turner CH et al : Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 : 613-620, 2000
PubMed
5) Bell KL, Loveridge N, Jordan GR et al : A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone 27 : 297-304, 2000
PubMed
6) Roschger P, Rinnerthaler S, Yates J et al : Alendronate increases degree and uniformity of mineralization in cancellousbone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 : 185-191, 2001
 
7) Borah B, Dufresne TE, Chmielewski PA et al : Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17 : 1139-1147, 2002
PubMed
8) Currey JD : Physical characteristics affecting the tensile failure properties of compact bone. J Biomech 23 : 837-844, 1990
PubMed
9) Katsumata T, Nakamura, T, Ohnishi H et al : Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 10 : 921-931, 1995
PubMed
10) Boivin GY, Chavassieux PM, Santora AC et al : Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 20 : 687-694, 2000
 
11) Roschger P, Gupta HS, Berzlanovich A et al : Constant mineralization density distribution in cancellous human bone. Bone 32 : 316-323, 2003
PubMed
12) Boivin G, Lips P, Ott SM et al : Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88 : 4199-4205, 2003
 

Chapter 7 ビスフォスフォネート治療の実際Q&A

P.140 掲載の参考文献
1) Masud T, Mulcahy B, Thompson AV et al : Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann, Rheum Dis 57 : 346-349, 1998
PubMed
2) Frediani B, Allegri A, Bisogno S et al : Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis : two years of continuous treatment. Clin Drug Invest 15 : 235-244, 1998
 
3) Wimalawansa SJ : A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104 : 219-226, 1998
 
4) Lindsay R, Cosman F, Lobo RA et al : Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis : a randomized controlled clinical trial. J Clin Endocrinol Metab 84 : 3076-3081, 1999
PubMed
5) Johnell O, Scheele WH, Lu Y et al : Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 : 985-992, 2002
 
6) Black DM, Greenspan SL, Ensrud KE et al : The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 : 1207-1215, 2003
 
7) Finkelstein JS, Hayes A, Hunzelman JL et al : The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 : 1216-1226, 2003
PubMed
P.145 掲載の参考文献
1) 水沼英樹 : 性腺機能低下と治療指針. 骨粗鬆症治療 1 : 29-33, 2002
Medical*Online
2) Rutgers-Verhage AR, deVries TW, Torringa MJ : No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 67 : 203-204, 2003
PubMed
P.149 掲載の参考文献
1) Reasner CA, Stone MD, Hosking DJ et al : Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77 : 1067-1071, 1993
PubMed
2) Chow CC, Chan WB, Li JK et al : Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88 : 581-587, 2003
PubMed
3) Khan AA, Bilezikian JP, Kung AW et al : Alendronate in primary hyperparathyroidism : a double-blind, randomized, placebocontrolled trial. J Clin Endocrinol Metab 89 : 3319-3325, 2004
 
4) Rossini M, Gatti D, Isaia G et al : Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16 : 113-119, 2001
PubMed
P.154 掲載の参考文献
1) Fleisch H : Bisphosphonates in Bone Disease : from the laboratory to the patient. 4th ed, San Diego, Academic Press, 2000
 
2) de Groen PC, Lubbe DF, Hirsch LJ et al : Esophagitis associated with the use of alendronate. N Engl J Med 335 : 1016-1021, 1996
PubMed
3) Lichtenberger LM, Romero JJ, Gibson GW et al : Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45 : 1792-1801, 2000
PubMed
4) Schnitzer T, Bone HG, Crepaldi G et al : Therapeutic equivalence of alendronate 70mg onceweekly and alendronate 10mg daily in the treatment of osteoporpsis. Aging (Milano) 12 : 1-12, 2000
 
5) Fisher JE, Rogers MJ, Halasy JM et al : Alendronate mechanism of action : geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96 : 133-138, 1999
PubMed
6) Suri S, Monkkonen J, Taskinen M et al : Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway : a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29 : 336-343, 2001
 
7) 新谷雅史, 別府謙一, 原裕子 : Teprenone (GGA) とエチドロネートの併用が閉経後骨量低下婦人の骨密度増加率に与える影響. Osteoporos Jpn 11 : 516-519, 2003
 
8) Shiraki M : Evidences and the taking measurements against G-I tract adverse events in amino bisphosphonate. CLINICAL CALCIUM 13 : 122-127, 2003
 
9) Blank MA, Gibson GW, Myers WR et al : Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 14 : 1215-1223, 2000
PubMed
10) Bauer DC, Black D, Ensrud K et al : Upper gastrointestinal tract safety profile of alendronate : the fracture intervention trial. Arch Intern Med 160 : 517-525, 2000
PubMed
P.158 掲載の参考文献
1) Sorensen OH, Crawford GM, Mulder H et al : Long-term efficacy of risedronate : a 5-year placebo-controlled clinical experience. Bone 32 : 120-126, 2003
PubMed
2) Black DM, Greenspan SL, Ensrud KE et al : The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 : 1207-1215, 2003
 
3) Mellstrom DD, Sorensen OH, Goemaere S et al : Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004 [Epub]
 
P.162 掲載の参考文献
1) Li J, Mori S, Kaji Y et al : Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14 : 969-979, 1999
PubMed
2) Fleisch H : Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16 : 437-440, 2001
PubMed
3) Balena R, Markatos A, Seedor JG et al : Long-term safety of the aminobisphosphonate alendronate in adultdogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276 : 277-283, 1996
PubMed
4) Peter CP, Cook WO, Nunamaker DM : Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14 : 74-79, 1996
 
5) 新薬承認情報集 : New Drug Approval Package (NAP). 平成14年, No9, 242-245
 
6) Lenehan TM, Balligand M, Nunamaker DM et al : Effect of EHDP on fracture healing in dogs. J Orthop Res 3 : 499-507, 1985
 
7) Manabe T*, Cao Y*, Mori S et al : The Effects of Antiresorptive Agents, Calcitonin and Alendronate, on the Femoral Fracture Healing of Cynomolgus Monkey (Macaca Fascicularis) Presentation Number : SU450
 
P.170 掲載の参考文献
1) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会 : 骨代謝マーカーを用いた骨粗鬆症治療の効果判定-骨密度から骨折予測まで- (ガイドライン2004年度版). Osteoporos Jpn 12 : 11-24, 2004
 
2) Kushida K, et al : The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis : a randomized, double-blind, active-controlled, double-dummytrial : Curr Ther Res Clin Exp 63 : 606-620, 2002
 
3) Shiraki M, Kushida K, Fukunaga M et al : A double-masked multicenter comparative study between alerldronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10 : 183-192, 1999
PubMed
4) Cummings SR, Black DM, Thompson DE et al : Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Trial. JAMA 280 : 2077-2082, 1998
PubMed
P.174 掲載の参考文献
1) Weinstein RS, Chen JR, Powers CC et al : Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109 : 1041-1048, 2002
PubMed
2) Wallach S, Cohen S, Reid DM et al : Effects of risedronate treatment on bone denisity and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67 : 277-285, 2000
 
P.179 掲載の参考文献
1) 山崎謙 : リセドロネート投与による短期血清NTXの変化と腰痛軽減効果の検討. Prog Med 24 : 1309-1315, 2004
 
2) Ascari E, Attardo-Parrinello G, Merlini G : Treatment of painful bone lesions and hypercalcemia. Eur J Haematol (Suppl) 51 : 135-139, 1989
PubMed
3) Lehmann HJ, Mouritzen U, Christgau S et al : Effect of bisphosphonates on cartilage turnover Assessed with anewly developed assay for Collagen type II degradation products. Ann Rheum Dis 61 : 530-533, 2002
PubMed
4) Frost HM : Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis. Osteoporos Int 8 : 13-15, 1998
PubMed
P.183 掲載の参考文献
1) Wimalawansa SJ : A four-yearr and omized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104 : 219-226, 1998
PubMed
2) Lindsay R, Cosman F, Lobo RA et al : Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis : a rondomized, controlled clinical trial. J Clin Endocrinol Metab 84 : 3076-3081, 1999
 
3) Bone HG, Greenspan SL, McKeever C et al : Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85 : 720-726, 2000
 
4) Harris ST, Eriksen EF, Davidson M et al : Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86 : 1890-1897, 2001
 
P.189 掲載の参考文献
1) Masud T, Mulcahy B, Thompson AV et al : Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57 : 336-349, 1998
 
2) Frediani B, Allegri A, Bisogno S et al : Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis 2 years of continuous treatment. Clin Drug Invest 15 : 235-244, 1998
 
P.195 掲載の参考文献
1) Weinstein RS : True strength. J Bone Miner Res 15 : 621-625, 2000
PubMed
2) Crarrey A, Guyatt G, Griffith L et al : Meta-analyses of therapies for postmenopausal osteoporosis. IX : Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23 : 570-578, 2002
PubMed
3) Rabin P, Thompson DE, Ross PD et al : Biochemical markers for prediction of 4-year response in bone mass during Bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33 : 150-158, 2003
 
4) Hochberg MC, Greenspan S, Wasnich RD et al : Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 : 1586-1592, 2002
PubMed
5) Tonino RP, Meunier PJ, Emkey R et al : Skeletal benefits of Alendronate : 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85 : 3109-3115, 2000
PubMed
6) Chaki O, Gorai I, Yoshikata H et al : Bone markers predict future BMD of Japanese postmenopausal osteoporotic women with hormone replacement therapy or Bisphosphonate treatment. J Bone Miner Res 17 (Suppl.) : S319, 2002
 
7) Fogelman I, Ribot C, Smith R et al : Risedronate reverses bone loss in postmenopausal women with low bone mass : Results from a multinational double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85 : 1895-1900, 2000
 
P.199 掲載の参考文献
1) 田中清, 白木正孝 : ビタミンDの基準値の国際比較. THE BONE 18 : 183-189, 2004
Medical*Online
2) 岡野登志夫, 津川尚子, 須原義智ほか : 高齢者を中心とする日本人成人女性のビタミンD栄養状態と骨代謝関連指標について. Osteoporos Jpn 12 : 76-79, 2004
 
3) 白木正孝 : 骨粗鬆症の薬物治療. Molecular Medicine 38 : 626-631, 2001
 
P.203 掲載の参考文献
1) Hans D, Dargent-Molina P, Schott AM et al : Ultrasonographic heel measurements to predict hip fracture in elderly women : the EPIDOS prospective study. Lancet 348 : 511-514, 1996
PubMed
2) 骨粗鬆症財団 : 骨粗鬆症検診. 老人保健法による骨粗鬆症予防マニュアル第2版. 日本医事新報社, 東京, p.61-85, 2000
 
3) Koh LK, Sedrine WB, Torralba TP et al : A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int 12 : 699-705, 2001
PubMed
P.206 掲載の参考文献
1) Okano H, Mizunuma H, Soda M et al : The long-term effect of menopause on postmenopausal bone loss in Japanese women : results from a prospective study. J Bone Miner, Res 13 : 303-309, 1998
 
2) Bone HG, Hosking D, Devogelaer JP et al : Ten years’experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004
 
3) Lindsay R, Cosman F, Lobo RA et al : Addition of alendronate to ongoing hormone replacement therapy in thetreatment of osteoporosis : a randomized, controlled clinical trial. J Clin Endocrinol Metab 84 : 3076-3081, 1999
 
4) Harris ST, Eriksen EF, Davidson M et al : Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86 : 1890-1897, 2001
 
5) Evio S, Tiitinen A, Laitinen K et al : Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 89 : 626-631, 2004
 
6) Ripps BA, VanGilder K, Minhas B et al : Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 48 : 761-766, 2003
PubMed
P.210 掲載の参考文献
1) Harada A, Matsui Y, Mizuno M et al : Japanese orthopedists’interests in prevention of fractures in the elderly from falls. Osteoporos Int 15 : 560-566, 2004
 
2) Glorieux FH, Bishop NJ, Plotkin H et al : Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339 : 947-952, 1998
PubMed
P.215 掲載の参考文献
1) Miller PD, Watts NB, Licata AA : Cyclical etidronate in the treatment of postmenopausal osteoporosis : efficacy and safety after seven years of treatment. Am J Med 103 : 468-476, 1997
PubMed
2) Liberman UA, Weiss SR, Broll J et al : Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 : 1437-1443, 1995
 
3) Black DM, Cummings SR, Karpf DB et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 : 1535-1541, 1996
 
4) Harris ST, Watts NB, Genant HK et al : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 : 1344-1352, 1999
 
5) Reginster J, Minne HW, Sorensen OH et al : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 : 83-91, 2000
 
6) Bone HG, Hosking D, Devogelaer JP et al : Ten years’experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004
 
7) Rosen CJ, Hochberg MC, Bonnick SL et al : Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis : a randomized double-blind study. J Bone Miner Res 20 : 141-151, 2005
PubMed
8) Lanza FL, Hunt RH, Thomson AB et al : Endoscopic comparison of esophageal and gastroduodenal effects of Risedronate and Alendronate inpostmenopausal women. Gastroenterology 119 : 631-638, 2000
 
P.220 掲載の参考文献
1) Johnell O, Scheele WH, Lu Y et al : Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 : 985-992, 2002
 
2) Ettinger B, Bilezikian JP : For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 87 : 983-984, 2002
 
3) Mashiba T, Hirano T, Turner CH et al : Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 : 613-620, 2000
PubMed
4) Komatsubara S, Mori S, Mashiba T et al : Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18 : 512-520, 2003
PubMed
P.225 掲載の参考文献
1) 折茂肇, 林泰史, 福永仁夫ほか : 原発性骨粗鬆症の診断基準 (2000年度改訂版). 日骨代謝誌 18 : 76-82, 2001
 
2) Genant HK, Li J, Wu CY et al : Vertebral fractures in osteoporosis : a new method for clinical assessment. J Clin Densitom 3 : 281-290, 2000
 
3) Genant HK, Wu CY, van Kuijk C et al : Vertebral fracture asssessment using a semiquantitative technique. J Bone Miner Res 8 : 1137-1148, 1993
 
4) Cummings SR, Black DM, Nevitt MC et al : Bone density at various sites for preditcion of hipfractures. The Study of Osteoporotic Fractures Research Group. Lancet 341 : 72-75, 1993
 
5) Faulkner KG, Genant HK, McClung M : Bilateral comparison of femoral bone density and hip axis length from single and fan beam DXA scans. Calcif Tissue Int 56 : 26-31, 1995
 
6) Blake GM, Patel R, Fogelman I : Peripheral or axial bone density measurements? J Clin Densiton 1 : 55-63, 1998
 
P.229 掲載の参考文献
1) Genant HK, Grampp S, Gluer CC et al : Universal standardization for dual X-ray absorptiometry : patient and phantom cross-calibration results. J Bone Miner Res 9 : 1503-1514, 1994
PubMed
2) Hanson J : Standardization of femur BMD. J Bone Miner Res 12 : 1316-1317, 1997
PubMed
3) 福永仁夫, 曽根照喜, 友光達志 : 骨塩定量検査機器の互換性. 骨塩定量検査機器の手引き 2002年版. 骨粗鬆症財団, ライフサイエンス出版, 2002
 
P.233 掲載の参考文献
1) 伊木雅之 : エビデンスに基づく勧告一覧表. 地域保健におけるエビデンスに基づく骨折・骨粗鬆症予防ガイドライン (伊木雅之編). 財団法人日本公衆衛生協会, 東京, 2004, p.85-86
 
2) 五訂食品成分表 (2004) (香川芳子監). 女子栄養大学出版部, 東京, 2004
 
3) 楊鴻生 : 骨粗鬆症と運動療法. 産婦人科治療 84 : 429-435, 2002
Medical*Online
4) 楊鴻生 : 基本的な対応 (食事, 運動, 理学療法). Progress in Medicine 22 : 1832-1837, 2002
Medical*Online
5) 楊鴻生 : 骨粗鬆症と生活習慣1. 運動. 骨粗鬆症治療 2 : 140-144, 2003
 
P.237 掲載の参考文献
1) 日本骨粗鬆症学会, 財団法人骨粗鬆症財団, 骨粗鬆症の治療 (薬物療法)に関するガイドライン作成ワーキンググループ : 骨粗鬆症の治療 (薬物療法) に関するガイドライン-2002年度改訂版-. Osteoporos Jpn 10 : 635-709, 2002
 
2) Dawson-Hughes B, Harris SS, Krall EA et al : Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337 : 670-676, 1997
PubMed
3) Hannan MT, Tucker KL, Dawson-Hughes B et al : Effect of dietary protein on bone loss in elderly men and women : the Framingham Osteoporosis Study. J Bone Miner Res 15 : 2504-2512, 2000
 
4) Evans CE, Chughtai AY, Blumsohn A et al : The effect of dietary sodium on calcium metabolism in premenopausal and postmenopausal women. Eur J Clin Nutr 51 : 394-399, 1997
PubMed
5) Lloyd T, Rollings N, Eggli DF et al : Dietary caffeine intake and bone status of postmenopausal women. Am J Clin Nutr 65 : 1826-1830, 1997
PubMed
6) Uenishi K, Ishida H, Kamei A et al : Calcium requirement estimated by balance study in elderly Japanese people. Osteoporos Int 12 : 858-863, 2001
PubMed
7) Pfeifer M, Begerow B, Minne HW et al : Effects of ashort-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15 : 1113-1118, 2000
 

Chapter 8 使用上の注意と対応

P.247 掲載の参考文献
1) Taggart H, Bolognese MA, Lindsay R et al : Upper gastrointestinal tract safety of risedronate : a pooled analysis of 9 clinical trials. Mayo Clin Proc 77 : 262-270, 2002
PubMed
2) Hodsman AB, Hanley DA, Ettinger MP et al : Efficacy and safety of human parathyroid hormone- (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88 : 5212-5220, 2003
PubMed
3) Powell JH, DeMark BR : Clinical pharmacokinetics of diphosphonates. In : Bone Resorption, Metastasis, and Diphosphonate. (Garattini G ed) Raven Press, New York, 1985, p.41-49
 
4) Gertz BJ, Holland SD, Kline WF et al : Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58 : 288-298, 1995
PubMed
5) Garzon P, Eisenberg MJ : Variation in the mineral content of commercially available bottled waters : Implications for health and disease. Am J Med 105 : 125-130, 1998
PubMed
6) BoneH G, Hosking D, Devogelaer JP et al : Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004
 
7) Cramer JA, Amonkar MM, Hebborn A et al : Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? ASBMR MO 434, 2004
 
8) Kushida K, Shiraki M, Nakamura T et al : The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis : a randomized, double-blind, active-controlled, double-dummy trial Curr Ther Res 63 : 606, 2002
 
9) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2004年度版). Osteoporos Jpn 12 : 191-204, 2004
 
10) Luckey M, Kagan R, Greenspan S et al : Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 11 : 405-415, 2004
PubMed

Chapter 9 治療効果の判定

P.257 掲載の参考文献
1) Genant HK, Engelke K, Fuerst T et al : Noninvasive assessment of bone mineral and structure : state of the art. J Bone Miner Res 11 : 707-730, 1996
 
2) Miller PD, Baran DT, Bilezikian JP et al : Practical clinical application of biochemical markers of bone turnover. J Clini Densitome 2 : 323-342, 1999
 
3) Calvo MS, Eyre DR, Gundberg CM : Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17 : 333-368, 1996
PubMed
4) Delmas PD, Eastell R, Garnero P et al : The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11 (Suppl 6) : S2-S17, 2000
 
5) 日本骨粗鬆症学会「骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会」 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2004年度版). Osteoporos Jpn 12 : 191-207, 2004
 
6) 高橋栄明, 岩谷力, 鈴木隆雄ほか : 骨粗鬆症患者QOL評価質問表 (1999年度版) の試用と2000年度版の作成. 日骨代謝誌 18 : 83-101, 2001
 

Chapter 10 癌に伴う骨病変とビスフォスフォネート

P.263 掲載の参考文献
1) Horwitz MJ, Stewart AF : Humoral hypercalcemia of malignancy. Primer on the metabolic bone diseases and disorders of mineral metabolism. (Favus MJ ed. ) American Society for Bone and Mineral Research. 2003, p.246-250
 
2) Clines GA, Guise TA : Hypercalcemia in hematologic malignancies and insolid tumors associated with extensive localized bone destruction. primer on the metabolic bone diseases and disorders of mineral metabolism. (Favus MJ ed. ) American Society for Bone and Mineral Research. 2003, p.221-256
 
3) Rosen LS, Gordon D, Tchekmedyian S et al : Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomizedtrial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 : 3150-3157, 2003
 
P.276 掲載の参考文献
1) Coleman RE : Skeletal complications of malignancy. Cancer 80 : 1588-1594, 1997
PubMed
2) Ramaswamy S, Ross KN, Lander ES et al : A molecular signature of metastasis in primary solid tumors. Nat Genet 33 : 49-54, 2003
PubMed
3) Hauschka PV, Mavrakos AE, Iafrati MD et al : Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261 : 12665-12674, 1986
PubMed
4) Hiraga T, Williams PJ, Mundy GR et al : The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61 : 4418-4424, 2001
PubMed
5) Sela J : Bone remodeling in pathologic conditions. A scanning electron microscopic study. Calcif Tissue Res 23 : 229-234, 1977
PubMed
6) Boyde A, Maconnachie E, Reid SA et al : Scanning electron microscopy in bone pathology : review of methods, potential and applications. Scan Electron Microsc 4 : 1537-1554, 1986
 
7) Suda T, Takahashi N, Udagawa N et al : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 : 345-357, 1999
PubMed
8) Mori Y, Shimizu N, Dallas M et al : Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 : 2149-2154, 2004
 
9) Yin JJ, Selander K, Chirgwin JM et al : TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103 : 197-206, 1999
 
10) Francini G, Petrioli R, Gonnelli S et al : Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 92 : 1468-1474, 2001
PubMed
11) Yi B, Williams PJ, Niewolna M et al : Tumor-derived platelet derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62 : 917-923, 2002
 
12) Yin JJ, Mohammad KS, Kakonen SM et al : A causalrole for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100 : 10954-10959, 2003
PubMed
13) Fleisch H, Reszka A, Rodan G et al : Bisphosphonates : Mechanism of action. In : Principles of Bone Biology (Bilezikian JP, Raisz LG, Rodan GA eds. ) , Academic Press, San Diego, 2001, p.1361-1385
 
14) Hillner BE, Ingle JN, Chlebowski RT et al : American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 : 4042-4057, 2003
 
15) Yoneda T, Hashimoto N, Hiraga T : Bisphosphonate actions on cancer. Calicf Tissue Int 73 : 315-318, 2003
PubMed
16) Saad F, Gleason DM, Murray RR et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
 
17) Hiraga T, Ueda A, Tamura D et al : Effects of oral UFT combined with or with outzoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 106 : 973-979, 2003
PubMed
18) Michigami T, Hiraga T, Williams PJ et al : The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75 : 249-258, 2002
PubMed
19) 平賀徹, 米田俊之 : 骨痛のメカニズム. 癌と骨病変, 松本俊夫, 福永仁夫, 米田俊之 (編) , メディカルレビュー社, 東京, 2004, p39-48
 
20) Diel IJ, Solomayer EF, Costa SD et al : Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 : 357-363, 1998
PubMed
21) Hiraga T, Williams PJ, Ueda A et al : Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10 : 4559-4567, 2004
PubMed
22) Giraudo E, Inoue M, Hanahan D : An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impaircervical carcinogenesis. J Clin Invest 114 : 623-633, 2004
PubMed

書評

最近チェックした商品履歴

Loading...